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Abstract 
Background/Aims: The viral integrase enzyme inhibitor dolutegravir is utilized for the 
treatment of immunodeficiency virus (HIV) infection. Knowledge on cytotoxicity of dolutegravir 
is limited. The present study thus explored, whether dolutegravir is able to trigger suicidal 
erythrocyte death or eryptosis, which is characterized by cell shrinkage and cell membrane 
scrambling with phosphatidylserine translocation to the erythrocyte surface. Cellular 
mechanisms involved in the triggering of eryptosis include increase of cytosolic Ca2+ activity 
([Ca2+]i), oxidative stress, ceramide, and activation of protein kinase C, p38 kinase, casein 
kinase, and caspases. The present study explored, whether Dolutegravir induces eryptosis 
and, if so, to gain insight into cellular mechanisms involved. Methods: Utilizing flow cytometry, 
phosphatidylserine exposure at the cell surface was estimated from annexin-V-binding, cell 
volume from forward scatter, [Ca2+]i from Fluo3-fluorescence, ROS formation from DCFDA 
dependent fluorescence, and ceramide abundance utilizing specific antibodies. Hemolysis was 
quantified from haemoglobin concentration in the supernatant. Results: A 48 hours exposure 
of human erythrocytes to dolutegravir significantly increased the percentage of annexin-V-
binding cells (≥ 4.8 µM), significantly increased hemolysis (19.1 µM), but did not significantly 
modify forward scatter. Dolutegravir significantly increased Fluo3-fluorescence (≥ 4.8 µM), 
DCFDA fluorescence (19.1 µM) and ceramide abundance (19.1 µM). The effect of dolutegravir 
on annexin-V-binding was significantly blunted by removal of extracellular Ca2+, but was not 
significantly modified by protein kinase C inhibitor staurosporine (1 µM), p38 kinase inhibitor 
SB203580 (2 µM), casein kinase inhibitor D4476 (10 µM) or pancaspase inhibitor zVAD (10 
µM). Conclusions: Dolutegravir triggers cell shrinkage and phospholipid scrambling of the 
erythrocyte cell membrane, an effect at least in part due to Ca2+ entry, ceramide formation 
and oxidative stress.
IntroductionDolutegravir, a viral integrase enzyme inhibitor [1-24], is effective in the treatment 
of human immunodeficiency virus (HIV) infection [1-14, 17, 19-27]. Side effects include 
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inhibition of the organic cation transporter 2 with decrease of creatinine clearance, diarrhea, 
headache, nausea, and insomnia [4, 17, 19, 20, 28]. Little is known about cytotoxicity of dolutegravir. A wide variety of xenobiotics [29-68] 
including antiviral drugs [69, 70] trigger eryptosis [56], the suicidal death of erythrocytes 
characterized by cell shrinkage [71] and cell membrane scrambling with phosphatidylserine 
translocation to the cell surface [56]. Induction of eryptosis has thus proven a sensitive 
measure of cytotoxicity [56]. Cellular mechanisms leading to eryptosis include increase 
of cytosolic Ca2+ activity ([Ca2+]i) [56], ceramide [72], oxidative stress [56, 73, 74], energy 
depletion [56], caspases [56, 75, 76], casein kinase 1α, Janus-activated kinase JAK3, protein 
kinase C, and p38 kinase [56]. Cellular mechanisms counteracting eryptosis include AMP 
activated kinase AMPK, cGMP-dependent protein kinase, PAK2 kinase [56], cyclin-dependent 
kinase CDK4 [77], mitogen- and stress-activated kinase MSK1/2 [78], and sorafenib/
sunitinib sensitive kinases [56]. 
The present study tested, whether dolutegravir stimulates eryptosis. To this end, human erythrocytes from healthy volunteers were exposed to dolutegravir and phosphatidylserine surface abundance, cell volume, [Ca2+]i, ROS formation, and ceramide abundance determined 
by flow cytometry. 
Materials and Methods 
Erythrocytes, solutions and chemicals
Fresh Li-Heparin-anticoagulated blood samples were kindly provided by the blood bank of the University 
of Tübingen. The study is approved by the ethics committee of the University of Tübingen (184/2003 V). The 
blood was centrifuged at 120 x g for 20 min at 21 °C and the platelets and leukocytes-containing supernatant 
was disposed. Erythrocytes were incubated in vitro at a hematocrit of 0.4% in Ringer solution containing (in 
mM) 125 NaCl, 5 KCl, 1 MgSO4, 32 N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid (HEPES; pH 7.4), 5 
glucose, 1 CaCl2, at 37°C for 48 hours. Where indicated, erythrocytes were exposed for 48 hours to dolutegravir 
(MedChem Express, Princeton, USA). To test for an involvement of kinases, erythrocytes were exposed for 48 
hours to a combination of dolutegravir and p38 kinase inhibitor SB203580 (Tocris bioscience, Bristol, UK), 
casein kinase inhibitor D4476 (Tocris bioscience, Bristol, UK) and protein kinase C inhibitor staurosporine 
(Enzo Life Sciences, Lörrach, Germany). The putative involvement of caspases was tested by the use of the 
pancaspase inhibitor zVAD (Enzo Life Sciences, Lörrach, Germany).
Annexin-V-binding and forward scatter 
After incubation under the respective experimental condition, a 150 µl cell suspension was washed in 
Ringer solution containing 5 mM CaCl2 and then stained with Annexin-V-FITC (1:200 dilution; ImmunoTools, 
Friesoythe, Germany) in this solution at 37°C for 15 min under protection from light. The annexin-V-
abundance at the erythrocyte surface was subsequently determined on a FACS Calibur (BD, Heidelberg, 
Germany). Annexin-V-binding was measured with an excitation wavelength of 488 nm and an emission 
wavelength of 530 nm. A marker (M1) was placed to set an arbitrary threshold between annexin-V-binding 
cells and control cells. The same threshold was used for untreated and dolutegravir treated erythrocytes. 
A dot plot of forward scatter (FSC) vs. side scatter (SSC) was set to linear scale for both parameters. The 
threshold of forward scatter was set at the default value of “52”.
Hemolysis
Following incubation, the erythrocyte suspension was centrifuged for 3 min at 1600 rpm, 4°C, and 
the supernatants were harvested. As a measure of hemolysis, the hemoglobin (Hb) concentration of the 
supernatants was determined photometrically at 405 nm. The absorption of the supernatant of erythrocytes 
lysed in distilled water was defined as 100% hemolysis. 
Intracellular Ca2+
After incubation, erythrocytes were washed in Ringer solution and loaded with Fluo-3/AM (Biotium, 
Hayward, USA) in Ringer solution containing 5 mM CaCl2 and 5 µM Fluo-3/AM. The cells were incubated 
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at 37°C for 30 min. Ca2+-dependent fluorescence intensity was measured with an excitation wavelength 
of 488 nm and an emission wavelength of 530 nm on a FACS Calibur. Afterwards, the geomean of the Ca2+ 
dependent fluorescence was determined.
Reactive oxygen species (ROS) 
Oxidative stress was determined utilizing 2’,7’-dichlorodihydrofluorescein diacetate (DCFDA). After 
incubation, a 150 µl suspension of erythrocytes was washed in Ringer solution and stained with DCFDA 
(Sigma, Schnelldorf, Germany) in Ringer solution containing DCFDA at a final concentration of 10 µM. 
Erythrocytes were incubated at 37°C for 30 min in the dark and washed two times in Ringer solution. The 
DCFDA-loaded erythrocytes were resuspended in 200 µl Ringer solution and ROS-dependent fluorescence intensity was measured at an excitation wavelength of 488 nm and an emission wavelength of 530 nm on 
a FACS Calibur (BD). Subsequently, the geomean of the DCFDA dependent fluorescence was determined.
Ceramide abundance
For the determination of ceramide, a monoclonal antibody-based assay was used. To this end, a 100 µl 
suspension of erythrocytes was stained for 1 hour at 37°C with 1 µg/ml anti ceramide antibody (clone MID 
15B4, Alexis, Grünberg, Germany) in PBS containing 0.1% bovine serum albumin (BSA) at a dilution of 1:10. 
The samples were washed twice with PBS-BSA. The cell suspension was subsequently stained for 30 minutes 
with polyclonal fluorescein isothiocyanate (FITC) conjugated goat anti-mouse IgG and IgM specific antibody 
(Pharmingen, Hamburg, Germany) diluted 1:50 in PBS-BSA. Unbound secondary antibody was removed by 
repeated washing with PBS-BSA. The samples were analyzed by flow cytometric analysis with an excitation 
wavelength of 488 nm and an emission wavelength of 530 nm. As a control, secondary antibody alone was 
used. Finally, the geomean of the ceramide-dependent fluorescence was determined.
Statistics
Data are expressed as arithmetic means ± SEM. As indicated in the figure legends, statistical analysis 
was made using ANOVA with Tukey’s test as post-test and t test as appropriate. n denotes the number of 
different erythrocyte specimens studied. Since different erythrocyte specimens used in distinct experiments are differently susceptible to triggers of eryptosis, the same erythrocyte specimens have been used for control 
and experimental conditions.
ResultsThe present study explored, whether dolutegravir stimulates eryptosis, the suicidal 
erythrocyte death. A hallmark of eryptosis is phospholipid scrambling of the cell membrane 
with phosphatidylserine translocation to the cell surface. Phosphatidylserine exposing 
erythrocytes were identified utilizing annexin-V-binding, as determined by flow cytometry. 
Prior to measurements, the erythrocytes were incubated for 48 hours in Ringer solution 
without or with dolutegravir (4.77-19.08 µM). As shown in Fig. 1, a 48 hours exposure to dolutegravir increased the percentage of phosphatidylserine exposing erythrocytes, an 
effect reaching statistical significance at 4.77 µM dolutegravir.
Hemoglobin concentration in the supernatant was determined in order to quantify 
hemolysis. As shown in Fig. 2, a 48 hours exposure to dolutegravir increased the percentage 
of hemolytic erythrocytes, an effect reaching statistical significance at 19.08 µM dolutegravir.
A second hallmark of eryptosis is cell shrinkage. Erythrocyte volume was thus estimated 
from forward scatter which was determined utilizing flow cytometry. The measurements 
were again performed after incubation of the erythrocytes for 48 hours in Ringer solution 
without or with dolutegravir (4.77-19.08 µM). As a result, after incubation for 48 hours, the 
forward scatter was similar in Ringer (515.8 ± 6.2, n = 19), in DMSO (531.9 ± 11.9, n = 19), 
in 4.77 µM dolutegravir (528.0 ± 10.9, n = 19), in 9.54 µM dolutegravir (519.2 ± 9.5, n = 19) 
and in 19.08 µM dolutegravir (515.6 ± 8.1, n = 19). Thus, dolutegravir did not significantly 
modify erythrocyte volume. 
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Fluo3 fluorescence was taken as a measure of cytosolic Ca2+ activity ([Ca2+]i). As 
illustrated in Fig. 3, following 48 hours incubation, the Fluo3 fluorescence was larger in the 
presence than in the absence of dolutegravir, a difference reaching statistical significance at 
4.77 µM dolutegravir concentration.A next series of experiments explored, whether the dolutegravir-induced cell shrinkage and translocation of phosphatidylserine or erythrocyte shrinkage required entry of 
extracellular Ca2+. To this end, erythrocytes were incubated for 48 hours in the absence 
or presence of 19.08 µM dolutegravir in the presence or nominal absence of extracellular 
Ca2+. As illustrated in Fig. 4, removal of extracellular Ca2+ significantly blunted the effect of 
dolutegravir on the percentage of annexin-V-binding erythrocytes. However, even in the 
absence of extracellular Ca2+, dolutegravir significantly increased the percentage of annexin-
V-binding erythrocytes. Thus, dolutegravir-induced cell membrane scrambling was in large 
part but not fully dependent on entry of extracellular Ca2+.
In order to explore the involvement of kinases in the stimulation of eryptosis by dolutegravir, 
experiments were repeated in the presence and absence of the respective kinase inhibitors. As 
a result, the increase of annexin-V-binding erythrocytes following treatment with dolutegravir 
Fig. 1. Effect of dolutegravir on 
phosphatidylserine exposure. A. 
Original histograms of annexin-V-binding of erythrocytes following 
exposure for 48 hours to Ringer so-
lution without (grey area) and with 
(black line) presence of 19.08 µM 
dolutegravir. B. Arithmetic means 
± SEM (n = 19) of erythrocyte an-
nexin-V-binding following incuba-
tion for 48 hours to Ringer solution 
without (white bar) or with (black 
bars) dolutegravir (4.77-19.08 
µM). For comparison, the effect of 
the solvent DMSO is shown (grey 
bar). ***(p<0.001) indicates signif-icant difference from the absence 
of dolutegravir (ANOVA).
Fig. 2. Effect of Dolutegravir on he-
molysis. Arithmetic means ± SEM 
(n = 5) of the percentage of hemo-lytic erythrocytes following incu-
bation for 48 hours to Ringer so-
lution without (white bar) or with 
(black bars) dolutegravir (4.77-
19.08 µM). For comparison, the ef-
fect of the solvent DMSO is shown 
(grey bar). **(p<0.01) indicates 
significant difference from the ab-
sence of dolutegravir (ANOVA).
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Fig. 3. Effect of Dolutegravir on cy-
tosolic Ca2+ activity. A. Original his-
tograms of Fluo3-fluorescence in erythrocytes following exposure for 
48 hours to Ringer solution without 
(grey area) and with (black line) 
presence of 19.08 µM dolutegravir. 
B. Arithmetic means ± SEM (n = 19) 
of erythrocyte Fluo3 fluorescence 
following incubation for 48 hours 
to Ringer solution without (white 
bar) or with (black bars) dolutegra-
vir (4.77-19.08 µM). For compari-
son, the effect of the solvent DMSO 
is shown (grey bar). *(p<0.05), 
***(p<0.001) indicate significant dif-ference from the absence of dolute-
gravir (ANOVA).
Fig. 4. Ca2+ sensitivity of dolutegravir-induced phosphatidylserine exposure. A,B. Original histograms of an-
nexin-V-binding of erythrocytes following exposure for 48 hours to Ringer solution without (grey area) and 
with (black line) dolutegravir (19.08 µM) in the presence (A) and absence (B) of extracellular Ca2+. C. Arith-
metic means ± SEM (n = 14) of annexin-V-binding of erythrocytes after a 48 hours treatment with Ringer 
solution without (white bars) or with (black bars) dolutegravir (19.08 µM) in the presence (left bars, +Ca2+) 
and absence (right bars, -Ca2+) of Ca2+. **(p<0.01),***(p<0.001) indicate significant difference from the ab-
sence of dolutegravir, ###(p<0.001) indicates significant difference from the presence of Ca2+ (ANOVA).
(19.08 µM) was similar in the absence (from 1.9 ± 0.4 % [n = 5] to 23.0 ± 2.7 % [n = 5]) and in the presence (from 1.9 ± 0.3 % [n = 5] to 21.8 ± 1.7 % [n = 5]) of p38 kinase inhibitor SB 203580 
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(2 µM). The increase of annexin-V-binding erythrocytes following treatment with dolutegravir 
(19.08 µM) was further similar in the absence (from 1.5 ± 0.2 % [n = 15] to 20.6 ± 1.8 % [n = 
15]) and in the presence (from 1.4 ± 0.1 % [n = 15] to 20.7 ± 1.8 % [n = 15]) of casein kinase 
inhibitor D4476 (10 µM). Moreover, the increase of annexin-V-binding erythrocytes following 
treatment with dolutegravir (19.08 µM) was similar in the absence (from 2.1 ± 0.5 % [n = 5] to 
23.1 ± 2.1 % [n = 5]) and in the presence (from 6.0 ± 0.9 % [n = 5] to 25.2 ± 1.7 % [n = 5]) of 
protein kinase C inhibitor staurosporine (1 µM). 
The putative involvement of caspases was tested utilizing pancaspase inhibitor zVAD. As a result, the increase of annexin-V-binding erythrocytes following treatment with dolutegravir 
(19.08 µM) was similar in the absence (from 1.5 ± 0.2 % [n = 14] to 23.2 ± 1.5 % [n = 14]) and in the presence (from 1.8 ± 0.2 % [n = 14] to 20.9 ± 1.7 % [n = 14]) of zVAD (10 µM).
Eryptosis is further stimulated by oxidative stress. Reactive oxygen species (ROS) was 
thus quantified utilizing 2′,7′-dichlorodihydrofluorescein diacetate (DCFDA). As illustrated 
in Fig. 5A,B, the DCFDA fluorescence was significantly higher following exposure to dolutegravir (19.08 µM) than in the absence of dolutegravir. 
Fig. 5. Effect of dolutegravir on erythrocyte ROS formation and ceramide abundance at the erythrocyte 
surface. A. Original histograms of DCFDA fluorescence in erythrocytes following exposure for 48 hours to 
Ringer solution without (grey area) and with (black line) presence of dolutegravir (19.08 µM). B. Arithmetic 
means ± SEM (n = 10) of the DCFDA fluorescence (arbitrary units) in erythrocytes exposed for 48 hours to 
Ringer solution without (white bar) or with (black bar) dolutegravir (19.08 µM). ***(p<0.001) indicates 
significant difference from the absence of dolutegravir (unpaired t test). C. Original histograms of ceramide 
abundance in erythrocytes following exposure for 48 hours to Ringer solution without (grey area) and with 
(black line) presence of 19.08 µM dolutegravir. D. Arithmetic means ± SEM (n = 6) of the ceramide abun-
dance (arbitrary units) in erythrocytes exposed for 48 hours to Ringer solution without (white bar) or with 
(black bar) presence of 19.08 µM dolutegravir. *(p<0.05) indicates significant difference from the absence 
of dolutegravir (unpaired t test).
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A further stimulator of eryptosis is ceramide. Ceramide abundance at the erythrocyte 
surface was thus quantified utilizing specific antibodies. As illustrated in Fig. 5C,D, the 
ceramide abundance was significantly higher following exposure to dolutegravir (19.08 µM) 
than in the absence of dolutegravir.
Discussion
The present observations reveal a toxic effect of dolutegravir on erythrocytes. Exposure of erythrocytes drawn from healthy individuals to dolutegravir is followed by cell membrane 
scrambling with phosphatidylserine translocation to the erythrocyte surface. The concentrations required for the effect are well in the range of reported plasma concentrations 
encountered following dolutegravir administration in man [28].The effect of dolutegravir on cell membrane scrambling was paralleled by increase of 
cytosolic Ca2+ activity ([Ca2+]i), was in large part blunted by removal of extracellular Ca2+ and was 
thus partially dependent on Ca2+ entry from the extracellular space. Nevertheless, even in the 
absence of extracellular Ca2+, dolutegravir stimulated cell membrane scrambling indicating that 
a small part of cell membrane scrambling did not require an increase of [Ca2+]i. Thus, dolutegravir 
apparently stimulated Ca2+ entry but by the same token sensitized the cell to the scrambling 
effect of Ca2+. Sensitization of erythrocytes for the scrambling effect of Ca2+ is observed following 
exposure to ceramide [56]. The triggering of cell membrane scrambling by dolutegravir was 
indeed paralleled by increase of ceramide abundance. Moreover, dolutegravir triggered 
eryptosis was paralleled by oxidative stress, a well known stimulator of eryptosis [56]. The 
effect of dolutegravir did not require the activity of p38 kinase, casein kinase or staurosporine 
sensitive kinases such as protein kinase C. The dolutegravir induced cell membrane scrambling 
was further insensitive to the presence of pancaspase inhibitor zVAD. Collectively, Ca2+ entry, ceramide and oxidative stress explain most, if not all the effect of dolutegravir on erythrocyte 
cell membrane scrambling. 
Despite the increase of [Ca2+]i dolutegravir did not trigger cell shrinkage. An increase of 
[Ca2+]i was expected to activate Ca2+ sensitive K+ channels thus leading to K+ exit, cell membrane 
hyperpolarization, Cl- exit and cellular loss of KCl with water. The mechanism preventing the 
cell shrinkage despite the increase of [Ca2+]i remained elusive. Potential mechanisms include 
interference with Na+/K+ ATPase activity with decrease of cellular K+ and thus Ca2+ induced 
hyperpolarization. Dolutegravir treatment is further followed by hemolysis with release of hemoglobin, 
which passes the renal glomerular filter, precipitates in the acidic lumen of renal tubules, 
occludes nephrons and thus may lead to renal failure [79]. As phosphatidylserine exposing erythrocytes are rapidly cleared from circulating blood, eryptosis may prevent hemolysis in 
vivo by removing the defective erythrocytes prior to hemolysis. Eryptosis may further serve to eliminate erythrocytes infected with the malaria pathogen Plasmodium. Excessive eryptosis may, however, lead to anemia as soon as the loss of erythrocytes surpasses the formation of new erythrocytes by erythropoiesis [56]. Phosphatidylserine exposing erythrocytes further 
adhere to the vascular wall [80], stimulate blood clotting and trigger thrombosis [81-83], thus impairing microcirculation [72, 81, 84-87]The sensitivity to dolutegravir may be enhanced in clinical conditions with accelerated eryptosis, such as dehydration [88], hyperphosphatemia [89], chronic kidney disease (CKD) 
[90-93], hemolytic-uremic syndrome [94], diabetes [95], hepatic failure [96], malignancy 
[56], sepsis [97], sickle-cell disease [56], beta-thalassemia [56], Hb-C and G6PD-deficiency 
[56], as well as Wilsons disease [98]. Patients with those conditions may, at least in theory, be particularly sensitive to dolutegravir-induced triggering of anemia and impairment of 
microcirculation. 
In conclusion, dolutegravir triggers erythrocyte cell membrane scrambling, an effect 
apparently involving Ca2+ entry, oxidative stress and ceramide.  
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